Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 0.94 |
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 0.94 |
| ▸ | CHRNA1 | P02708 | 5/20 | 0.94 |
| ▸ | CHRNG | P07510 | 5/20 | 0.94 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.94 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.94 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.94 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.94 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.94 |
| ▸ | CHRND | Q07001 | 5/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.94 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | HRH1 | P35367 | 1/20 | 0.94 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL12499296 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL38777 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29424575 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29354885 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL300444 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL60314 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL30679332 | 0.97 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL636116 | 0.95 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL5608195 | 0.95 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL1237221 | 0.95 | SLC6A2 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117100750-A | Pharmaceutical composition and application thereof | 深圳信立泰药业股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-114340608-B | Pharmaceutical composition and application thereof | 深圳信立泰药业股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116459255-A | Use of deuterated dextromethorphan and bupropion in combination in preparation of AD (analog to digital) excitation drugs | 深圳信立泰药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4183391-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-05-24 | — | — | EP | disclosed |
| CN-114340608-A | Pharmaceutical composition and application thereof | 深圳信立泰药业股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022017300-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-27 | — | — | WO | disclosed |
| US-20210393645-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2021-12-23 | — | — | US | disclosed |
| CN-106431943-B | Preparation method of bupropion hydrochloride crystal | 迪嘉药业集团有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20190262353-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2019-08-29 | — | — | US | disclosed |
| CN-108261402-A | The quick-release label preparation method of BUPROPIONE HCl enteric-coated sustained-release tablet | 上海星泰医药科技有限公司 | 2018-07-10 | — | — | CN | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | SLC6A3 266/4885SLC6A2 330/4885CHRNA1 104/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | SLC6A3 2839/4885SLC6A2 2832/4885CHRNA1 215/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | SLC6A3 777/4885SLC6A2 1018/4885CHRNA1 179/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | SLC6A3 333/4885SLC6A2 295/4885CHRNA1 99/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A3 1109/4885SLC6A2 1348/4885CHRNA1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.